Determining Process Quality Metrics for CMOs - Implementing quality by design makes the determination of quality metrics across CMOs and sponsors essential. - BioPharm International

ADVERTISEMENT

Determining Process Quality Metrics for CMOs
Implementing quality by design makes the determination of quality metrics across CMOs and sponsors essential.


BioPharm International
Volume 25, Issue 6, pp. 14-19

CASE STUDY

A global biopharmaceutical company needed to establish parameters to monitor processes at a CMO site to facilitate data analysis for science-based decision making and greater process understanding.

The sponsor required data from the CMO to fuel the same automated observational software tools used at its own sites to monitor large amounts of disparate data. The sponsor had limited knowledge regarding the CMO's processes and restricted access to CMO process experts, since collaboration was not required by the sponsor-CMO contractual agreement, which only allowed for limited data sharing.

Without a more informed starting point, preliminary parameters to monitor processes were based on educated guesses. The sponsor—with help from its analytical consultant team—set-up nearly 400 "suspect process and outcome parameters" to start the investigation. For example, the team monitored incoming material temperatures at a certain point in the process, under the suspicion that this variable would affect outcomes at the next process stage. It also predicted other parameters that had the potential to impact product quality, such as measuring the presence of synthesis-related impurities after ingredients were combined in one process step.

If the sponsor had been working at its own manufacturing site, it might have used a typical riskassessment approach, as guided by ICH Q9 Quality Risk Management (2). Authors from Pfizer have described this approach in detail:

"Risk assessment is the process used to prioritize parameters and attributes most likely to impact the product quality... The focal point of a QbD risk assessment is to be able to link quality measures and process controls to the product quality of the drug delivery system, i.e., safety, efficacy, and performance. A Quality Target Product Profile (QTPP) is an effective tool to help identify the Critical Quality Attributes (CQA) of the manufacturing process that link to product quality" (2).

Pfizer's approach requires access to experts and upfront risk assessment prior to setting up trending. Because the case study involved a CMO site, the team had to set up automated trend monitoring systems and then watch the data patterns to identify what was important.

To do so, the sponsor team compiled electronic data supplied by the CMO for analysis at the sponsor's headquarter using the sponsor's process intelligence software system. Through automated trend monitoring of the suspect parameters, the team could eventually narrow down the 400 initial parameters to those that were critical to quality outcomes. The software was configured to send alerts when data was trending out of specified limits, and the team also had access to data required for investigation of potential cause-and-effect linkages. This approach was much more interactive and real-time compared with the up-front method used in Pfizer's risk assessment approach and involved continuous process improvement using the ongoing analysis of data to increase process understanding.

The sponsor found this monitoring by exception method to be a helpful way of compensating for the limited access to process experts at the CMO site. It allowed the sponsor to see and learn from the data directly, and also facilitated collaboration by using data as a communication vehicle between CMO and sponsor.


Sidebar: Monitoring by exception
The above trend-monitoring approach was successful because the process monitoring systems were designed to monitor by exception (see sidebar), using an automated system to alert users when they should pay more attention to a specific parameter of concern and further analyze the data. However, the sponsor had to select suspect parameters for monitoring without knowing their criticality. Standard monitoring procedures were conducted, such as baselining data, removing special cause variation and estimating process capability, and control charts were developed to monitor process parameters by exception, which involved sending alerts when control and specification limits were violated. The true value of the control charts was not observed until a few months later when a deviation occurred at the CMO site. The sponsor had quick access to process monitoring information and could also use the charts to better communicate with the CMO site.

Following the selection of suspect parameters, the next phase for the sponsor team was narrowing these to determine the true CPPs. The sponsor team received alerts automatically when exceptions occurred, but if one parameter revealed a deviation, then the team knew it needed to monitor three to five additional parameters closely related to the measurement area. As a result, these real-word deviations provided a mechanism for filtering the suspect parameters over time, helping to determine CPPs.


Figure 1: Potential time saved through monitoring by exception compared with manual monitoring using spreadsheets.
When working with CMOs, sponsors often receive information regarding process indicator variables, but when the sponsor's analysts realize that a process is not functioning properly, they still have to pinpoint the root cause. Unless comprehensive contractual agreements exist with details of data access and analysis, it can be difficult for the sponsor to access the right data for root cause analysis and statistical modeling. This case study expanded the sponsor's process understanding and allowed for an open conversation with the CMO site regarding which additional indictors and process and outcome parameters would help both parties monitor processes in the future. In the end, the approach described above offered numerous benefits for both the sponsor and the CMO. Figure 1 shows the time saved through monitoring by exception.


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Bristol-Myers Squibb and Five Prime Therapeutics Collaborate on Development of Immunomodulator
November 26, 2014
Merck Enters into Licensing Agreement with NewLink for Investigational Ebola Vaccine
November 25, 2014
FDA Extends Review of Novartis' Investigational Compound for Multiple Myeloma
November 25, 2014
AstraZeneca Expands Biologics Manufacturing in Maryland
November 25, 2014
GSK Leads Big Pharma in Making Its Medicines Accessible
November 24, 2014
Author Guidelines
Source: BioPharm International,
Click here